Jeil Pharma Holdings Inc
Jeil Pharma Holdings Inc (KRX: 002620) is trading at ₩7,550.00, about ₹545 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 0.13% today. Jeil Pharma is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩7,480.00
Today's high
₩7,600.00
52 week low
₩6,050.00
52 week high
₩9,850.00
002620 opened at ₩7,560.00, closed previously at ₩7,560.00, and has traded between ₩6,050.00 and ₩9,850.00 over the past 52 weeks.
About
Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Furthermore, Jeil Pharma Holdings offers a broad selection of finished dosage forms addressing conditions such as bacterial, fungal, and viral infections; cardiovascular and endocrine disorders; neurological and gastrointestinal ailments; urological and oncological diseases. Its extensive range also features antihistamines, rheumatology, respiratory, otolaryngological, hepatic, and purgative agents. With a global presence, Jeil Pharma Holdings Inc. exports its products to approximately 40 countries, spanning regions like Southeast Asia, Central and South America, and Africa. Founded in 1959, the company's headquarters are situated in Seoul, South Korea.
Key statistics
Avg. volume
10.38K
Market cap
₩115.90B
P/E Ratio
13.73
Price-to-sales ratio
0.19
Enterprise value
₩239.60B
Free cash flow yield
-6.15%
Debt-to-equity ratio
0.59
Return on equity
4.59%
ROIC
1.88%
Beta
0.54
Dividend yield
0.93%
Last dividend
₩70.00
Financial overview
Revenue
₩657.61B
Earnings per share
₩953.37
Free cash flow
-₩7.89B
Net profit margin
1.35%
Gross margin
39.48%
EBITDA
₩30.02B
Revenue growth
-15.67%
Similar securities
This is not an investment recommendation
Jeil Pharma for Indian investors
Jeil Pharma is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Jeil Pharma for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Jeil Pharma’s current yield is 0.93%.Dividend tax explained
FAQs
Can I buy Jeil Pharma on Paasa?
Jeil Pharma (002620) has been listed on the Korea Exchange since 2000, in the Drug Manufacturers - Specialty & Generic industry. Jeil Pharma is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Jeil Pharma share cost in rupees?
One Jeil Pharma share is ₩7,550.00 — about ₹545 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Jeil Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Jeil Pharma shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Jeil Pharma price.
Does Jeil Pharma pay a dividend, and how is it taxed in India?
Yes. Jeil Pharma pays a dividend and the current yield is 0.93%; the last declared dividend was ₩70.00 per share, about ₹5.05. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Jeil Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Jeil Pharma?
Yes. Jeil Pharma is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.